Trovagene Investor Relations Trovagene Investor Relations Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial Thu, 16 Aug 2018 05:00:00 -0700 Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075 Onvansertib's product profile and attributes may offer the potential to provide significant clinical benefit with regard to efficacy and safety in patients with various types of cancer Wed, 15 Aug 2018 05:00:00 -0700 Trovagene Announces Second Quarter 2018 Highlights and Financial Results Fri, 03 Aug 2018 14:15:00 -0700 Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug Wed, 01 Aug 2018 05:00:00 -0700 Trovagene Presents Outlook for Second Half of 2018 Mon, 09 Jul 2018 05:00:00 -0700